Dexcom (NSDQ:DXCM) today shared results from two studies of continuous glucose monitors, including its next-generation G7 CGM.
San Diego-based Dexcom presented the studies during the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD).
The first study, the Mobile study, published in JAMA, observed 175 ethnically and socioeconomically diverse adults (30 years old or older) over eight months across 15 clinical sites with type 2 diabetes who are receiving diabetes care from a primary care provider trying to manage their diabetes using basal or background insulin but not faster-acting insulin at meals, according to a news release.
Two-thirds of the participants were assigned to use Dexcom CGM and the rest used a traditional blood glucose meter. The group using Dexcom’s CGM spent an average of 3.8 hours more each day within the optimal range of blood glucose levels, 3.6 hours less each day in the very high glucose range and had a reduction in CGM-measured hypoglycemia.
In total, 63% of patients using CGM had an HBA1c of less than 8%, compared to just 39% in the traditional fingerstick group. Adherence and satisfaction were also high in the CGM group, the company said.
Dexcom’s second study of its next-generation G7 interoperable CGM drew from clinical trials supporting its efforts toward CE mark submission and U.S. pre-pivotal work.
Across approximately 360 sensor sections, 99% of readings were clinically accurate and safe for treatment decisions. The mean absolute relative difference (MARD) — the average of the absolute error between all CGM values and matched reference values — came in at 8.7%.
The company touts its G7 wearable CGM as 60% smaller than the G6 and says it contains a smaller all-in-one sensor applicator and transmitter with a 30-minute warm-up time before use. It possesses interoperability with insulin delivery devices and maintains accuracy, as demonstrated in the study, Dexcom said.
“Initial clinical data has only strengthened our conviction that Dexcom G7 will build upon the high accuracy standard already established by our G6 CGM system,” Dexcom EVP & CTO Jake Leach said in the release. “The G7 is a completely redesigned CGM; our users will get a whole suite of new features that we believe will enhance the customer experience that has become synonymous with Dexcom.”
